RESPIRE trial of therapeutic for all strains of COVID-19 gets underway in Germany
Investigators hope ATR-002 drug will also be effective against ‘Long-Covid’ Tübingen, Germany-based Atriva Therapeutics, a biopharmaceutical company that is pioneering the development of host-targeting antiviral therapies, has enrolled its first patient in its Phase II RESPIRE [1] trial in COVID-19. Prof. Martin Witzenrath, M.D., Vice Director Department of Infectious Diseases and Respiratory Medicine, […]
